Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

Yahoo Finance • 2 days ago

Regeneron Announces Investor Conference Presentations

Regeneron Pharmaceuticals, Inc. TARRYTOWN, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 2026 Jefferies Global Healthcare Conference in London at... Full story

Yahoo Finance • 3 days ago

US Stock Market Today: S&P 500 Futures Edge Higher On ISM Manufacturing Test

The Morning Bull - US Market Morning Update Monday, Nov, 2 2026 US stocks are set for a cautiously positive open, with index futures inching higher as investors focus on fresh US activity data. The single driver today is the October ISM M... Full story

Yahoo Finance • 5 days ago

Regeneron (REGN) stock trades up, here is why

Regeneron (REGN) stock trades up, here is why What happened? Shares of biotech company Regeneron (NASDAQ:REGN) jumped 11.5% in the afternoon session after the company reported a 36% increase in third-quarter 2026 revenue to $5.1 billion,... Full story

Yahoo Finance • 6 days ago

Regeneron (NASDAQ:REGN) surprises with strong Q3 2026, stock soars

Regeneron (NASDAQ:REGN) surprises with strong Q3 2026, stock soars Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street's expectations in Q3 2026, with revenue up 36.3% year on year to $5.12 billion. Its non-GAAP... Full story

Yahoo Finance • 7 days ago

What to expect from Regeneron’s (REGN) Q3 earnings

What to expect from Regeneron's (REGN) Q3 earnings Biotech company Regeneron (NASDAQ:REGN) will be announcing earnings results tomorrow before market hours. Here's what investors should know. Regeneron beat analysts' revenue expectations... Full story

Yahoo Finance • 16 days ago

Strong Dupixent Trajectory Anchors Regeneron Pharmaceuticals’ (REGN) Solid Financial Results

Longleaf Partners, managed by Southeastern Asset Management, released its third-quarter 2026 investor letter for its "Partners Fund". The letter can be downloaded here. Coming into this year, the Fund's three-year annualized returns were a... Full story

Yahoo Finance • 17 days ago

Sensorion Announces the Appointment of Peter Weber, MD, MBA, as Chief Medical Officer

Dr. Weber, an otologist and neurotologist who led the clinical development of the first FDA-approved gene therapy for genetic hearing loss, joins as SENS-601 advances into the clinic MONTPELLIER, France & CAMBRIDGE, Mass., October 19, 202... Full story

Yahoo Finance • 20 days ago

Did Earnings Beat Just Shift Regeneron Stock Investment Narrative?

Regeneron Pharmaceuticals reported Q2 revenue of US$4.29b, up 16.7% year on year, alongside positive 84 week Phase 3 OPTIMA data for Pasatru in adults with fibrodysplasia ossificans progressiva. The data supports its recently approved use... Full story

Yahoo Finance • 22 days ago

Biotech Stocks To Watch: Regeneron Partner Has Breakout In Sight

Boosted by its exclusive agreement with Regeneron, Kiniksa Pharmaceuticals stands among the top biotech stocks to watch. Continue Reading... Full story

Yahoo Finance • 23 days ago

Why A Biotech M&A Wave May Hit This Winter

Biotech stocks have slumped from their August highs. But experts say renewed M&A, likely coming, could catalyze them. Continue Reading... Full story

Yahoo Finance • 28 days ago

Is Biohaven (BHVN) Quietly Recasting Its Oncology Strategy Through Deeper Ties With Regeneron?

In September 2026, Biohaven Ltd. announced a clinical supply agreement with Regeneron Pharmaceuticals to test BHV-1530 in combination with cemiplimab (Libtayo) in patients with solid tumors, following earlier monotherapy and preclinical da... Full story

Yahoo Finance • last month

Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets

Biotech companies are strange businesses to think about in terms of competitive advantages. A software company can lock customers into an ecosystem for years. A manufacturer can have a cost advantage. A biotech company, meanwhile, can spen... Full story

Yahoo Finance • last month

Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks

Global bond yields recently hit multidecade highs, raising borrowing costs and putting pressure on many high growth sectors. When money gets more expensive, investors often look harder at balance sheets and valuations. That is where select... Full story

Yahoo Finance • last month

Why Regeneron (REGN) Stock Is Trading Lower Today

Why Regeneron (REGN) Stock Is Trading Lower Today What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 4% in the afternoon session after the biotechnology company expanded its immunology alliance with Sanofi on terms tha... Full story

Yahoo Finance • last month

Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls

Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled... Full story

Yahoo Finance • last month

Regeneron drug said to cut muscle loss when combined with Novo's semaglutide

[Doctor doing research in lab during COVID-19] Morsa Images * An experimental weight-loss drug being developed by Regeneron (REGN [https://seekingalpha.com/symbol/REGN]) used in combination with Novo Nordisk's (NVO [https://seekingalpha... Full story

Yahoo Finance • last month

Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

Regeneron Pharmaceuticals, Inc. REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting prec... Full story

Yahoo Finance • last month

Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies

Sanofi Winthrop Industrie Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron,... Full story

Yahoo Finance • last month

Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts

Key Points Interested in Regeneron Pharmaceuticals, Inc.? Here are five stocks we like better. EYLEA HD is gaining momentum, accounting for roughly 60% of EYLEA franchise sales in the second quarter. Regeneron expects low- to mid-teens se... Full story

Yahoo Finance • last month

Vault CRM Extends Market Leadershipas Another Top 20 Biopharma Chooses Veeva

With 190 live customers and 14 top 20 biopharma commitments, Vault CRM is the fastest path to AI PLEASANTON, Calif., Sept. 23, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced a new top 20 biopharma commitment, adding to r... Full story